BREAKING NEWS

BeyondSpring announces submission of New Drug Application (NDA) to U.S. FDA and China NMPA for Plinabulin and G-CSF combination for the prevention of chemotherapy-induced neutropenia (CIN).
Read more

NEWS & MEDIA

We’re not only at the front lines of therapeutic advancement, we’re also continuously making headlines in healthcare, business, and research markets.

PRESS RELEASES

BeyondSpring Announces Pricing of Ordinary Shares

BeyondSpring Announces Pricing of Ordinary Shares June 19, 2020 NEW YORK, June 19, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology...

read more

BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention

BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention June 15, 2020 Met Primary Endpoint of Rate of Severe...

read more

MEDIA

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.